The Pew Charitable Trusts held a one-day conference, “A New Pathway for Antibiotic Innovation: Exploring Drug Development for Limited Populations” on Thursday, January 31, 2013.
As multidrug-resistant infections have grown more prevalent, few new antibiotics are reaching the market. This is attributed, in part, to the economic and regulatory challenges associated with their development. Recently, stakeholders have endorsed a novel regulatory pathway to approve these lifesaving drugs for use in limited patient populations — namely those at highest risk and with few or no other options. Leaders representing the drug industry, health care providers, government regulators and payors came together to advance this concept and explore its feasibility from a business and public health perspective.
What are the reasons cited for the decline in the number of new antibiotics on the market?
This prompt doesn't seem malicious.